Immunotherapy-Associated Pseudomembranous Colitis

Am J Gastroenterol. 2019 Nov;114(11):1708. doi: 10.14309/ajg.0000000000000282.

Authors

Trilokesh D Kidambi¹, Peiguo Chu², Jeffrey K Lee³, James L Lin¹

Affiliations

¹ Division of Gastroenterology, City of Hope National Medical Center, Duarte, California, USA.
² Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
³ Department of Gastroenterology, Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA.

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / adverse effects
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects
Carcinoma, Hepatocellular / etiology
Carcinoma, Hepatocellular / therapy
Coinfection
End Stage Liver Disease / etiology
End Stage Liver Disease / therapy
Endoscopy, Gastrointestinal / methods*
Enterocolitis, Pseudomembranous* / diagnosis
Enterocolitis, Pseudomembranous* / drug therapy
Enterocolitis, Pseudomembranous* / etiology
Enterocolitis, Pseudomembranous* / physiopathology
Glucocorticoids / administration & dosage
Hepatitis B, Chronic / complications*
Hepatitis C, Chronic / complications*
Humans
Intestinal Mucosa* / diagnostic imaging
Intestinal Mucosa* / pathology
Male
Middle Aged
Neoplasm Staging
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Glucocorticoids
pembrolizumab

Grants and funding

K07 CA212057/CA/NCI NIH HHS/United States